Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

The challenge of clinical end points in sickle cell disease

Kenneth I. Ataga

Blood (2023) 142 (24): 2047–2054.

https://doi.org/10.1182/blood.2023021220

Published: 2023

Journal Articles

Development of a Genetic Risk Score for Albuminuria in Pediatric Patients with Sickle Cell Anemia

Rima Zahr, Guolian Kang, Sara Rashkin, Yutaka Yasui, Csaba Kovesdy, Clifford M Takemoto, Jeffrey D. Lebensburger, Mitchell Weiss, Santosh L. Saraf, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 1141.

https://doi.org/10.1182/blood-2023-185213

Published: 2023

Journal Articles

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials

Abdullah Kutlar, Vikas Joshi, Andreas Brueckner, Julie Kanter, Darla K. Liles, Jeremie Lincy, Rahul Manjare, Yvonne Dei Adomakoh, Matthew M. Heeney, Mariane de Montalembert, Deborah Keefe, Kwaku Marfo, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 1139.

https://doi.org/10.1182/blood-2023-188639

Published: 2023

Journal Articles

A Systematic Review and Meta-Analysis to Evaluate Hydroxyurea at Escalated Dose Versus Fixed Low-Dose Hydroxyurea in Adults with Sickle Cell Disease

Ugochi Olivia Ogu, Ayesha Mukhopadhyay, Kruti Patel, Marquita Nelson, Kay Strahan, Lin Wu, Matthew P Smeltzer, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 5289.

https://doi.org/10.1182/blood-2023-184937

Published: 2023

Journal Articles

Predictive Capacity of Plasma and Urinary Biomarkers for Persistent Albuminuria in Patients with Sickle Cell Disease

Laila Elsherif, Vimal K. Derebail, Yihan Tang, Lara C. Scott, Kammie L. Patillo, David Wichlan, Kristina Landes, Paula McCune, Laura R. Loehr, Payal Desai, Robert Cronin, Laura Y. Zhou, Fei Zou, Jianwen Cai, David M. Pollock, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2023-187610

Published: 2023

Journal Articles

Safety and Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study

Julie Kanter, Parth Patwari, Payal Desai, Kenneth I. Ataga, Shelley E. Crary, Sophie Lanzkron, Joshua Field, Yu-Che Chung, Linda T. Wang, Björn Mellgård, Van Anh (Vika) Nguyen, Victor R. Gordeuk

Blood (2023) 142 (Supplement 1): 149.

https://doi.org/10.1182/blood-2023-189090

Published: 2023

Journal Articles

Persistent Albuminuria and Chronic Kidney Disease in Adults with Sickle Cell Disease: Results from a Multicenter Natural History Study

Vimal K. Derebail, Laura Y. Zhou, Yihan Tang, Laila Elsherif, Kammie L. Patillo, David Wichlan, Kristina Landes, Paula McCune, Laura R. Loehr, Payal Desai, Robert Cronin, Jianwen Cai, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 1124.

https://doi.org/10.1182/blood-2023-179675

Published: 2023

Journal Articles

Prevalence and Time Trends of Oral Anticoagulant Utilization in Adults with Sickle Cell Disease

Ming Chen, Jane S Hankins, Min Zhang, Justin Gatwood, James E Bailey, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2023-188030

Published: 2023

Journal Articles

Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)

Vimal K Derebail, Laura Y Zhou, Laila Elsherif, Kammie L Patillo, David Wichlan, Kristina Landes, Paula McCune, Laura R Loehr, Robert M Cronin, Payal C Desai, Jianwen Cai, Kenneth I Ataga

Blood (2022) 140 (Supplement 1): 2545–2546.

https://doi.org/10.1182/blood-2022-163314

Published: 2022

Journal Articles

Age-related Impact of the CDC's 2016 Guideline for Prescribing Opioids for Chronic Pain on Opioid Prescribing Levels and Health Outcomes among the Patients with Sickle Cell Disease

Hyeun Ah Kang, Yahan Zhang, Jamie Barner, Kenneth I Ataga

Blood (2022) 140 (Supplement 1): 5112–5113.

https://doi.org/10.1182/blood-2022-165436

Published: 2022

Journal Articles

Uremic Metabolites Are Associated with Albuminuria and Estimated Glomerular Filtration Rate (eGFR) in Sickle Cell Disease

Laila Elsherif, Yanxin Chen, Kammie L. Patillo, Paula McCune, Qingning Zhou, Kenneth I. Ataga

Blood (2022) 140 (Supplement 1): 11103–11105.

https://doi.org/10.1182/blood-2022-170516

Published: 2022

Journal Articles

Association of Novel Urinary Protein Biomarkers with Persistent Albuminuria in Patients with Sickle Cell Disease

Laila Elsherif, Praghalathan Kanthakumar, Jeremiah Afolabi, Ayesha Mukhopadhyay, Matthew P. Smeltzer, Adebowale Adebiyi, Kenneth I. Ataga

Blood (2022) 140 (Supplement 1): 11100–11102.

https://doi.org/10.1182/blood-2022-170362

Published: 2022

Journal Articles

Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease

Rima Zahr, Akram Mohammed, Surabhi Naik, Daniel Faradji, Jeffrey D. Lebensburger, Kenneth I Ataga, Robert L Davis

Blood (2022) 140 (Supplement 1): 2530–2531.

https://doi.org/10.1182/blood-2022-165572

Published: 2022

Journal Articles

Association of Thrombospondin-1 Gene Polymorphism with Elevated Tricuspid Regurgitant Velocity in Sickle Cell Anemia

Parul Rai, Sara Rashkin, Victoria I Okhomina, Vijaya Joshi, Kenneth I. Ataga, Jane S Hankins, Guolian Kang, Jeremie H. Estepp

Blood (2021) 138 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2021-150845

Published: 2021

Journal Articles

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Santosh L. Saraf, Kenneth I. Ataga, Vimal K. Derebail, Claire C. Sharpe, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Yifan Zhang, Pablo Bartolucci

Blood (2021) 138 (Supplement 1): 3096.

https://doi.org/10.1182/blood-2021-149849

Published: 2021

Journal Articles

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase IIa CROSSWALK-c Trial Evaluating the Efficacy of Crovalimab As Adjunct Treatment in the Prevention of Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Michael Callaghan, Kenneth I. Ataga, Lucia De Franceschi, Caterina Minniti, Nadiesh Balachandran, Diane-Charlotte Imbs, Thomas Perretti, Julia Ramos, Alexandre Sostelly, Pablo Bartolucci

Blood (2021) 138 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2021-151222

Published: 2021

Journal Articles

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Pablo Bartolucci, Kenneth I. Ataga, Michael U. Callaghan, Lucia De Franceschi, Caterina Minniti, Ari Alexandrou, Diane-Charlotte Imbs, Richard Fox, Himika Patel, Alexandre Sostelly, Jonathan Schimmel

Blood (2021) 138 (Supplement 1): 3108.

https://doi.org/10.1182/blood-2021-147854

Published: 2021

Journal Articles

Outcomes of Patients with Sickle Cell Disease and Eskd in the Usrds Registry

Rima Zahr, Marianne McPherson Yee, Kenneth I. Ataga, Jeffrey Winer, Jeffrey D. Lebensburger

Blood (2021) 138 (Supplement 1): 4056.

https://doi.org/10.1182/blood-2021-152989

Published: 2021

Journal Articles

Age-Associated Decline in Blood Parameters in Individuals with Sickle Cell Disease

Samuel Robert Wilson, Marcella H Boynton, Marcus A. Carden, Emily Ciccone, Vimal K. Derebail, Kenneth I. Ataga

Blood (2021) 138 (Supplement 1): 970.

https://doi.org/10.1182/blood-2021-145919

Published: 2021

Journal Articles

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Wally R Smith, MD, Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Olufolake A. Adisa, MDMSc, Miranda Bailey, Nicholas Ramscar, MBBS, Ashley Bonner, PhD, Stephen Brown, PhD, Laura Pastor, MSc

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140428

Published: 2020

NARROW

The challenge of clinical end points in sickle cell disease

Development of a Genetic Risk Score for Albuminuria in Pediatric Patients with Sickle Cell Anemia

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials

A Systematic Review and Meta-Analysis to Evaluate Hydroxyurea at Escalated Dose Versus Fixed Low-Dose Hydroxyurea in Adults with Sickle Cell Disease

Predictive Capacity of Plasma and Urinary Biomarkers for Persistent Albuminuria in Patients with Sickle Cell Disease

Safety and Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study

Persistent Albuminuria and Chronic Kidney Disease in Adults with Sickle Cell Disease: Results from a Multicenter Natural History Study

Prevalence and Time Trends of Oral Anticoagulant Utilization in Adults with Sickle Cell Disease

Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)

Age-related Impact of the CDC's 2016 Guideline for Prescribing Opioids for Chronic Pain on Opioid Prescribing Levels and Health Outcomes among the Patients with Sickle Cell Disease

Uremic Metabolites Are Associated with Albuminuria and Estimated Glomerular Filtration Rate (eGFR) in Sickle Cell Disease

Association of Novel Urinary Protein Biomarkers with Persistent Albuminuria in Patients with Sickle Cell Disease

Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease

Association of Thrombospondin-1 Gene Polymorphism with Elevated Tricuspid Regurgitant Velocity in Sickle Cell Anemia

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase IIa CROSSWALK-c Trial Evaluating the Efficacy of Crovalimab As Adjunct Treatment in the Prevention of Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Outcomes of Patients with Sickle Cell Disease and Eskd in the Usrds Registry

Age-Associated Decline in Blood Parameters in Individuals with Sickle Cell Disease

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only